Acta Scientific Pharmaceutical Sciences (ASPS)(ISSN: 2581-5423)

Short Communication Volume 5 Issue 1

Wide Spread Use of Monoclonal Antibody would have Prevented Massive Death Rate from Covid-19 Infection

Tapan K Chaudhuri* and Richard Hoffler

Hampton, VA and San Antonio, TX, USA

*Corresponding Author: Tapan K Chaudhuri, Hampton, VA, USA. E-mail:

Received: January 27, 2021; Published: January 30, 2020


  If the use of Monoclonal Antibody (MoAb) to COVID-19 saved the life of the President of the United States and several other people in his circle, then why are we not using the same therapy for everybody else. If we aggressively motivate to start the use of MoAb to COVID-19 infection, we can prevent a lot of deaths. It’s a magic bullet, it’s a cure.



Citation: Tapan K Chaudhuri and Richard Hoffler. “Wide Spread Use of Monoclonal Antibody would have Prevented Massive Death Rate from Covid-19 Infection". Acta Scientific Pharmaceutical Sciences 5.2 (2021): 67.


Acceptance rate32%
Acceptance to publication20-30 days
Impact Factor1.020

Indexed In

News and Events

  • Certification for Review
    Acta Scientific certifies the Editors/reviewers for their review done towards the assigned articles of the respective journals.
  • Submission Timeline for Upcoming Issue
    The last date for submission of articles for regular Issues is January 15, 2022.
  • Publication Certificate
    Authors will be issued a "Publication Certificate" as a mark of appreciation for publishing their work.
  • Best Article of the Issue
    The Editors will elect one Best Article after each issue release. The authors of this article will be provided with a certificate of “Best Article of the Issue”.
  • Welcoming Article Submission
    Acta Scientific delightfully welcomes active researchers for submission of articles towards the upcoming issue of respective journals.
  • Contact US